Skip to content

HCSC

Does HCSC cover Wegovy for Heart Disease Risk Reduction?

Yes. HCSC covers Wegovy for heart disease risk reduction with prior authorization if your BMI is 27 or higher. Other policy requirements and your plan's benefits also apply.

Policy document

  • Employer: Covered with requirements. See the qualification pathways below.

Earliest policy review June 2, 2026. How we verify · Check your exact plan

Full requirements: Wegovy for Heart Disease Risk Reduction (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

CV risk reduction in adults with established CVD and obesity/overweight

All of:

  • Requested use is to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal MI, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight
  • Requested agent is Wegovy
  • Patient has a pretreatment BMI ≥ 27 kg/m2
  • Patient will use optimized pharmacotherapy for established cardiovascular disease in combination with Wegovy
  • Patient does NOT have any FDA labeled contraindications

Plus any one of:

  • History of myocardial infarction
  • History of stroke
  • Peripheral artery disease as defined by intermittent claudication with ankle-brachial index < 0.85 at rest, or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease

Documentation to bring

  • Documentation of established cardiovascular disease (CAD, ACS, history of MI, angina, revascularization, PCI/CABG, stroke, TIA, carotid or arterial stenosis, PAD including aortic aneurysm, all of atherosclerotic origin)
  • Documentation of qualifying CV event: MI, stroke, or PAD (with ABI < 0.85, revascularization, or amputation due to atherosclerotic disease)
  • Baseline BMI documentation (≥ 27 kg/m2)
  • Documentation of current or planned optimized pharmacotherapy for established cardiovascular disease

Quantity limits

  • 0.25 MG/0.5ML, 0.5 MG/0.5ML, 1 MG/0.5ML — 8 pens per 180-day supply (84-day)
  • 1.7 MG/0.75ML, 2.4 MG/0.75ML — 4 pens per 28-day supply
  • 7.2 MG/0.75ML — 4 pens per 28-day supply
  • 1.5 MG tablet, 4 MG tablet, 9 MG tablet — 60 tablets per 180-day supply (84-day)
  • 25 MG tablet — 30 tablets per 30-day supply

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • Renewal: At renewal, patient must have had clinical benefit with Wegovy AND will continue optimized pharmacotherapy for established cardiovascular disease. Initial qualifying CV event documentation and BMI threshold are not explicitly re-verified at renewal.

Not covered when

  • Any FDA labeled contraindications to the requested agent

Exceptions

  • BCBS_NM_Fully_Insured_or_HIM: May be approved if patient does not have FDA labeled contraindications AND the requested indication is a rare disease AND patient has another FDA labeled indication or compendia-supported indication.
  • Ohio_Fully_Insured_or_HIM_SHOP: May be approved if member resides in Ohio, plan is Fully Insured or HIM Shop (SG), no FDA labeled contraindications, AND patient has another FDA labeled or compendia-supported indication OR prescriber submits two articles from major peer-reviewed journals.

Policy note: Established CVD is defined broadly as: CAD, ACS, history of MI, stable or unstable angina, coronary or other arterial revascularization, prior PCI/CABG, stroke, TIA, carotid or other arterial stenosis, or PAD including aortic aneurysm, all of atherosclerotic origin. The PAD qualifying criterion specifically requires: intermittent claudication with ABI < 0.85 at rest, OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease. GDMT specified as 'optimized pharmacotherapy for established cardiovascular disease' without naming specific drug classes.

Policy effective May 18, 2026 · verified June 2, 2026 · source: Hcsc Weight Management Prog Sum · View policy document (PDF)

Open on its own page →

Questions people ask
Does HCSC cover Wegovy?
Yes. HCSC covers Wegovy for heart disease risk reduction with prior authorization if your BMI is 27 or higher. Other policy requirements and your plan's benefits also apply.
How long does a Wegovy approval last with HCSC?
Heart Disease Risk Reduction — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.
What does HCSC require to renew Wegovy?
Heart Disease Risk Reduction — Applies to Employer plans. At renewal, patient must have had clinical benefit with Wegovy AND will continue optimized pharmacotherapy for established cardiovascular disease. Initial qualifying CV event documentation and BMI threshold are not explicitly re-verified at renewal.
How current is this information?
The oldest review date among the policies on this page is June 2, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under HCSC: Mounjaro, Ozempic, Zepbound

Wegovy under other plans: Illinois Medicaid, Molina Healthcare, Oklahoma Medicaid, Elevance Health, Highmark, Premera, Regence, Wellmark

All insurance plans · All medications

Summary of HCSC's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.